Table 1.
Antimicrobial Susceptibility Testing of Pseudomonas aeruginosa Blood Cultures
| Pseudomonas aeruginosa 1* | Pseudomonas aeruginosa 2 | |
|---|---|---|
| Amikacin** | S | S |
| Aztreonam | R | I |
| Cefepime | R | R |
| Ceftazidime | R | S |
| Ceftolozane/Tazobactam | I | S |
| Ciprofloxacin | I | I |
| Imipenem | R | R |
| Levofloxacin | R | R |
| Meropenem | R | R |
| Piperacillin/Tazobactam | R | S |
| Tobramycin | S | S |
| Ceftazidime/Avibactam MIC (mcg/mL)*** |
R 64 |
|
| Cefiderocol MIC (mcg/mL)**** |
S 0.5 |
S 0.5 |
S, susceptible; I, intermediate; R, resistant; MIC, minimum inhibitory concentration; mcg, microgram; mL, milliliter.
Testing performed by Kirby–Bauer disk diffusion unless otherwise specified.
* Carba-R PCR negative; multiple isolates recovered with identical susceptibility pattern, stable cefiderocol MIC.
** Susceptibility prior to CLSI M 100-Ed33.
*** E-test.
**** Broth microdilution at Laboratory Specialists, Inc. (Westlake, OH) and ARUP Laboratories (Salt Lake City, Utah).